Objective To evaluate the efficacy and safety of telbivudine combined with bicyclol in the treatmentof patients with chronic hepatitis B.Methods 133 untreated cases of HBeAg-positive chronic hepatitis B patients were selected and randomly divided into 2 groups as experiment group and control group.In the experiment group 67 cases were given 600 mg of telbivudine orally combined with 75 mg of bicyclol once-daily, whereas in the control group 66 cases were only treated with oral dose of 600 mg telbivudine daily.Both the groups were on continuous medication for 104 weeks.serum aminotransferase levels and virological indicators were observed.Results serum aminotransferase were significantly in both groups, and more significant change in the experimental group (P<0.01) at 12W, the HBeAg seroconversion rate and seroconversion in both the groups were compared.There were no statistically significant differences between the groups.with prolonged treatment, at 24W, 52W, 104W, serum HBeAg negative conversion rate in the experimental group were higher than that of the control group.HBV DNA levels of the two groups were significantly decreased, but there were not statistically significant difference on HBV DNA undetectable rate at different time point. (P>0.05) .At 52 weeks, 2 cases and 3 cases of drug resistance occurred in the treatment group and control group respectively.The resistance rates were 4.69% and 7.81%, respectively, there was no statistically significant difference (P>0.05) .At 104 weeks, resistance in the treatment group were in 5 cases and resistance in the control group were in 13 cases and resistance rates were 7.81% and 20.31%, respectively, there was statistically significant difference (P<0.05) .The two groups did not observe any drug-related adverse reactions.Conclusion telbivudine in combination with bicyclol treatment for HbeAg positive chronic hepatitis B is effective and safe.
DownLoad: